Product Description
Mechanisms of Action: MAP2K Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Arthritis, Rheumatoid|Psoriasis
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT02214888 | P2 |
Terminated |
Arthritis, Rheumatoid |
2004-01-01 |
|
| NCT02211885 | P1 |
Completed |
Healthy Volunteers |
2002-11-01 |
|
| NCT02209753 | P2 |
Completed |
Psoriasis |
2002-09-01 |
|
| NCT02209805 | P1 |
Completed |
Healthy Volunteers |
2001-03-01 |